Integrum

Integrum Financial Debt Ratio

The Financial Debt Ratio of Integrum (INTEG B.ST) as of Nov 3, 2026 is 2.39 %. In the previous year, Financial Debt Ratio was 3.90 % — a change of -38.78% (lower).

Financial Debt Ratio

2.39 %

YoY

-38.78%

Last updated:

Financial Debt Ratio of Integrum is 2025 2.39 % . Financial Debt Ratio of Integrum was 2024 3.90 % . It decreases by -38.78% lower compared to the previous year.

The Integrum Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
7.54 SEK
Jan 1, 2019
5.65 SEK
Jan 1, 2020
2.25 SEK
Jan 1, 2021
4.03 SEK
Jan 1, 2022
0.32 SEK
Jan 1, 2023
4.79 SEK
Jan 1, 2024
3.90 SEK
Jan 1, 2025
2.39 SEK
The Integrum Financial Debt Ratio history
YEARFinancial Debt RatioYoY
2.39 %-38.78%
3.90 %-18.68%
4.79 %+1,388.48%
0.32 %-92.02%
4.03 %+79.34%
2.25 %-60.19%
5.65 %-25.12%
7.54 %-55.00%
16.76 %-65.01%
47.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integrum Stock analysis

What does Integrum do? Integrum AB generates revenue through the sale of medical devices, primarily the OPRA Implant System, which enables osseointegration for direct skeletal attachment of artificial limbs. The company also offers neural prosthetics technology, allowing bionic prostheses to connect directly to bone, nerves, and muscles, alongside a treatment method for phantom limb pain using machine learning, augmented reality, and virtual reality. Prosthetic components required to link the OPRA Implant System to external prostheses are sold as part of the product suite. Customers include individuals with amputations seeking advanced prosthetic solutions, with the company targeting medical professionals and healthcare providers who recommend and implement these systems. The OPRA Implant System, neural prosthetics, and phantom limb pain treatment are key revenue drivers, with the company focusing on high-end medical devices for specialized applications. Prosthetic components serve as complementary products, supporting the primary systems. The business model relies on direct sales to healthcare institutions and clinics specializing in prosthetics and rehabilitation, where the technology is integrated into patient care pathways. Integrum AB's product portfolio is centered around innovative medical solutions for amputees, with the OPRA Implant System as the flagship offering. The neural prosthetics and phantom limb pain treatment methods differentiate the company in the medical device market, addressing both functional and therapeutic needs. Sales of prosthetic components further enhance revenue streams by supporting the full integration of the implant system with external prosthetic devices. Integrum is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrum stock

Financial Debt Ratio of Integrum is 2.39 % in 2025.

Financial Debt Ratio of Integrum changed from 3.90 % to 2.39 %, representing a -38.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Integrum since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Integrum with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Integrum

All Key Metrics — Integrum